Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
Shigeru ImotoKun WangXi-Wen BiGuangyu LiuYoung-Hyuck ImSeock-Ah ImSung Hoon SimTakayuki UenoManabu FutamuraMasakazu ToiYasuhiro FujiwaraSung Gwe AhnJeong Eon LeeYeon Hee ParkShintaro TakaoMari Saito ObaYuko KitagawaMasahiko NishiyamaPublished in: Breast cancer (Tokyo, Japan) (2023)
Combination therapy may be considered for longer survival under some conditions in oligometastatic BC.